Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia

J Neuropsychiatry Clin Neurosci. Summer 1989;1(3):249-52. doi: 10.1176/jnp.1.3.249.

Abstract

Oxiracetam is a recently synthesized nootropic that was tested as a potential treatment for cognitive decline in patients with multi-infarct dementia (MID) and primary degenerative dementia (PDD). Subjects were 34 MID patients and 39 PDD patients who met entrance criteria for the study. A repeated measures ANOVA showed significant improvement in both patients with MID and patients with PDD for word fluency. The total score on the Relatives' Assessment of Global Symptomatology-Elderly showed significant improvement for patients with PDD. The average score on the Instrumental Activities of Daily Living Scale, however, showed a significant decline for patients with PDD.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living / psychology
  • Aged
  • Aged, 80 and over
  • Dementia / drug therapy*
  • Dementia / psychology
  • Dementia, Multi-Infarct / drug therapy*
  • Dementia, Multi-Infarct / psychology
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Psychotropic Drugs / therapeutic use*
  • Pyrrolidines / therapeutic use*

Substances

  • Psychotropic Drugs
  • Pyrrolidines
  • oxiracetam